Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Dollar Stabilizes Amid Fragile US-Iran Ceasefire as Markets Watch Hormuz Strait 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
U.S. Natural Gas Market Faces Short-Term Pressure but Long-Term Demand Surge 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
U.S. Markets Post Strong Weekly Gains Despite Middle East Tensions and Rising Energy Prices 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Middle East Conflict Threatens Global Economic Stability, World Bank Warns 
Japan Consumer Confidence Drops Sharply Amid Rising Fuel Costs and Middle East Tensions 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Asian Stocks Rally on Ceasefire Hopes and Bargain Buying 
U.S. Inflation Surges in March as Iran War and Tariffs Drive Prices Higher 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Samsung Biologics revealed on Monday, Sept. 18, that it has closed a contract manufacturing organization deal (CMO) with Bristol-Myers Squibb to produce immunotherapy medications until 2030. The contract is said to be worth $242 million.
Bristol-Myers Squibb is one of the long-term customers of Samsung Biologics, so this is just another deal for a new production request. They have been working together for the CMO business since 2013. In any case, on the part of the Korean biopharmaceutical company, this contract has been added to its streak of wins for CMO projects this year alone.
Collectively, the company is close to hitting the KRW3 trillion or $2.26 billion mark for all of its deals so far in 2023. Reaching this amount is said to be a milestone for Samsung Biologics as it is happening for the first time.
As per The Korea Herald, as of September 2023, the Incheon-based biotechnology firm was able to secure contract manufacturing deals with 14 of the world’s top 20 pharmaceuticals. Novartis and Pfizer are the other major brands that signed large-scale agreements with the company.
Meanwhile, Samsung Biologics agreed to produce immunotherapies of Bristol-Myers Squibb. These will be manufactured in its fourth plant in the span of seven years.
An official of the biotech arm of the Samsung Group said, “Securing the latest deal was possible as Samsung Biologics has proved itself as a reliable contract manufacturer to its global partners, with its large production capacity, fast manufacturing speeds and consistent, high-quality output.”
“Our relationship with Bristol Myers Squibb spans over a decade, and we are proud and excited to help bring important medicines to patients around the world,” Samsung Biologics’ president and chief executive officer, John Rim, further said in a statement. “This collaboration with Bristol Myers Squibb underscores our commitment to expediting the delivery and ensuring the continuous supply of client pipelines, enabled by our commitment to manufacturing quality, innovation, and capacity.”
Photo by: Samsung Biologics Newsroom
